StockNews.com Begins Coverage on Avinger (NASDAQ:AVGR)

Analysts at StockNews.com initiated coverage on shares of Avinger (NASDAQ:AVGR) in a report released on Thursday. The firm set a “hold” rating on the medical device company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Avinger in a research report on Thursday, March 21st.

Avinger Trading Down 1.6 %

NASDAQ AVGR opened at $3.68 on Thursday. The firm has a market capitalization of $5.85 million, a P/E ratio of -0.14 and a beta of 1.26. The business has a fifty day simple moving average of $3.44 and a 200 day simple moving average of $3.31. Avinger has a 12 month low of $2.50 and a 12 month high of $18.00.

Avinger (NASDAQ:AVGR) last released its quarterly earnings results on Wednesday, March 20th. The medical device company reported ($3.93) EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($4.57). The company had revenue of $1.91 million during the quarter, compared to analyst estimates of $2.52 million. As a group, sell-side analysts predict that Avinger will post -2.08 EPS for the current fiscal year.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.